Cites del registre
Cita APA (7th ed.)
Al-Odat, O. S., Al-Odat, O. S., Elbezanti, W. O., Elbezanti, W. O., Gowda, K., Srivastava, S. K., . . . Pandey, M. K. (2024). KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis. Frontiers Media S.A.
Copiat
No s'ha pogut copiar
Cita Chicago (17th ed.)
Al-Odat, Omar S., et al. KS18, a Mcl-1 Inhibitor, Improves the Effectiveness of Bortezomib and Overcomes Resistance in Refractory Multiple Myeloma by Triggering Intrinsic Apoptosis. Frontiers Media S.A, 2024.
Copiat
No s'ha pogut copiar
Cita MLA (9th ed.)
Al-Odat, Omar S., et al. KS18, a Mcl-1 Inhibitor, Improves the Effectiveness of Bortezomib and Overcomes Resistance in Refractory Multiple Myeloma by Triggering Intrinsic Apoptosis. Frontiers Media S.A, 2024.
Copiat
No s'ha pogut copiar
Atenció: Aquestes cites poden no estar 100% correctes.